Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma

Table 5 Stratified analysis on the association between single nucleotide polymorphism genotype and hepatocellular carcinoma risk according to hepatitis B virus infection status

SNP	HBsAg-positive				HBsAg-negative
	Case	Control	OR (95%CI)1	P value1	Case	Control	OR (95%CI)1	P value1
rs2305952
TT	624	80	Reference		177	803	Reference
TC	161	24	0.86 (0.53-1.42)	0.56	48	214	1.05 (0.72-1.52)	0.80
CC	9	5	0.25 (0.08-0.80)	0.02a	0	12	-	1.00
TC/CC	170	29	0.76 (0.48-1.21)	0.25	48	226	0.99 (0.68-1.43)	0.95
rs17006625
AA	411	60	Reference		115	560	Reference
AG	323	42	1.15 (0.75-1.76)	0.54	89	404	1.07 (0.77-1.48)	0.68
GG	60	7	1.36 (0.59-3.17)	0.47	21	65	1.79 (1.02-3.12)	0.04a
AG/GG	383	49	1.18 (0.78-1.77)	0.44	110	469	1.17 (0.86-1.59)	0.32
rs515255
CC	301	39	Reference		107	372	Reference
TC	377	52	0.93 (0.59-1.46)	0.75	92	501	0.64 (0.46-0.89)	0.01a
TT	116	18	0.81 (0.44-1.50)	0.51	26	156	0.69 (0.36-0.96)	0.03a
TC/TT	493	70	0.90 (0.59-1.37)	0.62	118	657	0.63 (0.46-0.86)	0.003a

¹OR and 95%CI after adjusting for age, sex, nationality, smoking, drinking and family history of hepatocellular carcinoma.

^aP < 0.05 was considered statistically significant. OR: Odds ratio; CI: Confidence interval; SNPs: Single nucleotide polymorphisms.